Deepson Bio Honored with Presidential Award for Innovative dementia โTreatment Technology
Seoul, South Korea – December 5, 2025 โฃ – Deepson Bio co., Ltd. has โขbeen awardedโฃ the President’s Award, the highest honor at the ‘2025 Korea Invention Patent Exhibition,’ for its groundbreaking ultrasound-based technology โฃtargeting dementia. The company received the prestigious award on December 3rd.
Theโ Korea โInvention Patent competition, โhosted by the Ministryโ of Intellectual Property and organized by the korea Invention Promotion Association, is the nation’s largest event recognizing and promoting superior domestic technologies and patented products. โขOnly one institution receives the President’s Award annually, makingโฃ Deepson Bio’s achievement notably meaningful. Winning products are currently on display at COEX in Seoul until December 6th.
Deepson Bio’s award-winning โtechnology โฃcenters around a patented ultrasonic device (patent number 10-2317379,inventor: Gujin Jeong) designed to stimulate the brain’s lymphatic system and facilitate the removal of waste โฃproducts,including โbeta-amyloid – โคa key factorโค in the progress โขof dementia.โ The company initially received the Presidential Award for this technology in 2021.
This non-invasive,non-pharmacological approach offers โa โขpotential advantage over existing dementia treatments by minimizing risks such as brain-blood barrier disruption,allergicโ reactions,and cerebral hemorrhage. Deepson Bio believes the technologyโค holds promiseโ for treating a range of degenerative brain diseases, including normal pressure hydrocephalus.
Building on this technology, โDeepson Bio has independently developed “Neuclare,” a medical device for dementia treatment. The company has completed exploratory clinical trialsโ and recently received approval โฃfrom theโฃ Ministry of Food and Drug Safety to begin confirmatory clinical trials. These trials are slated to take place at seven leading hospitals acrossโค south Korea: Seoul National University Bundang โขHospital, Hallym University Dongtan Sacred โคHeart โคHospital, Ewha Womans University Mokdong Hospital, Ewha Womans University โคseoul Hospital, Soonchunhyang University Cheonan hospital, Inha University Hospital, and Catholic University St. Vincent Hospital.
“Receiving this Presidential Award is the result of official recognition of the potential โขof ultrasoundโ devices for dementia treatment to change the paradigm โof โขdementia treatment solutions,” said Lee Dong-hyeok, CEO of Deepson Bio. “We will accelerate commercialization by quickly completing the ongoing confirmatory clinical trial of Nuclair,while also accelerating our entry into overseas dementia treatment marketsโ such as the United States and Japan.”